Linomide

Discontinued Product

1461 has been discontinued.

View all Antiangiogenics products.
说明: Immunomodulator with antiangiogenic properties
化学名: 1,2-Dihydro-4-hydroxy-N,N-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide
纯度: ≥99% (HPLC)
说明书
引用文献
评论
文献 (1)

生物活性 for Linomide

Linomide is an immunomodulator with stimulatory and antitumor properties. Inhibits in vivo apoptosis of T cells and inhibits angiogenesis in rats in vivo.

技术数据 for Linomide

分子量 308.33
公式 C18H16N2O3
储存 Store at RT
纯度 ≥99% (HPLC)
CAS Number 84088-42-6
PubChem ID 54676478
InChI Key SGOOQMRIPALTEL-UHFFFAOYSA-N
Smiles CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=CC=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

参考文献 for Linomide

参考文献是支持产品生物活性的出版物。

Gonzalo et al (1994) Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur.J.Immunol. 24 48 PMID: 8020570

Ichikawa et al (1992) The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res. 52 3022 PMID: 1591718

Vukanovic et al (1993) Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res. 53 1833 PMID: 7682157

按标靶查看相关产品

关键词: Linomide, Linomide supplier, Immunomodulators, antiangiogenics, Antiangiogenics, 1461, Tocris Bioscience

篇 Linomide 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 Linomide 的引用文献。

Linomide 的评论

目前没有该产品的评论。 Be the first to review Linomide and earn rewards!

Have you used Linomide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Angiogenesis in Cancer Poster

Angiogenesis in Cancer Poster

This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.